Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine

Proteomics - Clinical Applications

Volumn 9, Issue 9-10, 2015, Pages 928-937

  Baldelli, Elisa ^a,b   Haura, Eric B ^c   Crinò, Lucio ^b   Cress, Douglas W ^c   Ludovini, Vienna ^b   Schabath, Matthew B ^c   Liotta, Lance A ^a   Petricoin, Emanuel F ^a   Pierobon, Mariaelena ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Individualized therapy; Laser capture microdissection; Nonsmall cell lung cancer; Pathway activation mapping; Reverse phase protein microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG BIOPSY; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVERSE PHASE PROTEIN MICROARRAY; LUNG TUMOR; METABOLISM; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LASER CAPTURE MICRODISSECTION; LUNG NEOPLASMS; PHOSPHOPROTEINS; PRECISION MEDICINE; PROTEIN ARRAY ANALYSIS;

EID: 84942878049     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400056     Document Type: Article

References (34)

1. Siegel, R., Ma, J., Zou, Z., Jemal, A. et al., Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
2. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
3. Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S. et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
4. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T. et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693-1703.
5. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T. et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368, 2385-2394.
6. Cappuzzo, F., Jänne, P. A., Skokan, M., Finocchiaro, G. et al., MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 2009, 20, 298-304.
7. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H. et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947-957.
8. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S. et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362, 2380-2388.
9. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J. et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
10. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C. et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
11. Pierobon, M., Wulfkuhle, J., Liotta, L., Petricoin, E. et al., Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene 2015, 34, 805-814.
12. Zupa, A., Improta, G., Silvestri, A., Pin, E. et al., A pilot characterization of human lung NSCLC by protein pathway activation mapping. J. Thorac. Oncol. 2012, 7, 1755-1766.
13. Improta, G., Zupa, A., Fillmore, H., Deng, J. et al., Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J. Proteome Res. 2011, 10, 3089-3097.
14. Wulfkuhle, J. D., Yau, C., Gallagher, R. I., Wolf, D. et al., Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2- tumors. Cancer Res. 2012, 72, Abstract nr P3-04-02.
15. Pierobon, M., Silvestri, A., Spira, A., Reeder, A. et al., A pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J. Proteome Res. 2014, 13, 2846-2855.
16. Jameson, G. S., Petricoin, E., Sachdev, J. C., Liotta, L. A. et al., A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer. J. Clin. Oncol. 2013, 31(suppl), abstr TPS11123.
17. Wulfkuhle, J. D., Speer, R., Pierobon, M., Laird, J. et al., Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J. Proteome Res. 2008, 7, 1508-1517.
18. Wulfkuhle, J. D., Berg, D., Wolff, C., Langer, R. et al., Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 2012, 18, 6426-6435.
19. Mueller, C., deCarvalho, A. C., Mikkelsen, T., Lehman, N. L. et al., Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res. 2014, 74, 818-828.
20. Rekhter, M. D., Chen, J., Molecular analysis of complex tissues is facilitated by laser capture microdissection: critical role of upstream tissue processing, Cell Biochem. Biophys. 2001, 35, 103-113.
21. Espina, V., Edmiston, K. H., Heiby, M., Pierobon, M. et al., A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell Proteomics 2008, 7, 1998-2018.
22. VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J. et al., Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer. Mol. Cell Proteomics 2008, 7, 1902-1924.
23. Pin, E., Federici, G., Petricoin, E. III, Preparation and use of reverse protein microarrays. Curr. Protoc. Protein Sci. 2014, 75, 27.7.1-27.7.29.
24. Wang, F., Wang, S., Wang, Z., Duan, J. et al., Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. J. Exp. Clin. Cancer Res. 2012, 18, 31-65.
25. Emery, I. F., Battelli, C., Auclair, P. L., Carrier, K., Hayes, D. M., Response to gefitinib and erlotinib in non-small cell lung cancer: a restrospective study. BMC Cancer 2009, 18, 9-333.
26. Assadi, M., Lamerz, J., Jarutat T., Farfsing, A. et al., Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol. Cell Proteomics 2013, 12, 2615-2622.
27. Rapkiewicz, A., Espina, V., Zujewski, J. A., Lebowitz, P. F. et al., The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer Cytology. 2007, 111, 173-84.
28. Calvert, V. S., Collantes, R., Elariny, H., Afendy, A. et al., A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46, 166-172.
29. Silvestri, A., Colombatti, A., Calvert, V. S., Deng, J. et al., Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest. 2010, 90, 787-796.
30. Aaltonen, K. E., Ebbesson, A., Wigerup, C., Hedenfalk, I. et al., Laser capture microdissection (LCM) and whole genome amplification (WGA) of DNA from normal breast tissue -optimization for genome wide array analyses. BMC Res. Notes 2011, 4, 69.
31. Murphy, S. J., Cheville, J. C., Zarei, S., Johnson, S. H. et al., Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012, 19, 395-406.
32. El-Serag, H. B., Nurgalieva, Z. Z., Mistretta T. A., Finegold M. J. et al., Gene expression in Barrett's esophagus: laser capture vs. whole tissue. Scand. J. Gastroenterol. 2009, 44, 787-795.
33. Harrell, J. C., Dye, W. W., Harvell, D. M., Sartorius CA, Horwitz, K. B., Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin. Exp. Metastasis. 2008, 25, 81-88.
34. Zheng, J., Garg, S., Wang, J., Loose, D. S., Hauer-Jensen, M., Laser capture microdissected mucosa versus whole tissue specimens for assessment of radiation-induced dynamic molecular and pathway changes in the small intestine. PLoS One 2013, 8, e53711.